Clinical Trial

A Study to Evaluate the Efficacy and Safety of Concomitant Use of Eplontersen and ALXN2220 Compared With Eplontersen and Placebo for Adults Participants With ATTR-CM

Study acronym: ATTRiumph
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this randomised, double-blind, placebo-controlled, multicenter study is to evaluate the efficacy and safety of concomitant use of eplontersen and ALXN2220 compared with eplontersen and placebo in adult participants with Transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).
Protocol Amendment History 3 changes
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-07-15
critical Recruitment opened 2026-06-18
critical Primary endpoint(s) modified 2026-06-11
Trial Details
NCT Number NCT07608354
Lead Sponsor AstraZeneca
Conditions Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Enrollment 326 participants
Start Date 2026-06-11
Primary Completion 2029-02-06 (estimated)
Study Completion 2029-02-06 (estimated)
Updated on ClinicalTrials.gov 2026-07-14